ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Background: Filgotinib (FIL) is a selective JAK1 inhibitor with an affinity 30-fold higher than JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Methods: We co...

Full description

Bibliographic Details
Main Authors: Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, Elenia Laurino, Francesca Bartoli, Arianna Damiani, Francesca Li Gobbi, Anna Panaccione, Luca Di Cato, Laura Niccoli, Bruno Frediani, Marta Mosca, Serena Guiducci, Fabrizio Cantini
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Journal of Personalized Medicine
Subjects:
rheumatoid arthritis
filgotinib
real-life
Online Access:https://www.mdpi.com/2075-4426/13/9/1303

Internet

https://www.mdpi.com/2075-4426/13/9/1303

Similar Items